Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, 2-period, fixed-sequence study assessing the impact of multiple dose rifabutin administration on the pharmacokinetics (PK) of doravirine in healthy adult subjects

Next Previous
Search
Trial Profile

An open-label, 2-period, fixed-sequence study assessing the impact of multiple dose rifabutin administration on the pharmacokinetics (PK) of doravirine in healthy adult subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doravirine (Primary) ; Rifabutin (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics

    • Most Recent Events

    • 24 Jun 2020 According to a Merck media release, poster on "Dose Adjustment of Doravirine Mitigates the Pharmacokinetic Interaction With the Moderate Rifabutin" (Poster Presentation PEA0083. S. Kalilieh et al.) will be presented at 23rd International AIDS Conference (AIDS 2020: Virtual) taking place virtually from July 6-10, 2020.
    • 03 May 2018 Results published in the Journal of Clinical Pharmacology
    • 20 Apr 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top